NDA 019921 · Allergan
Ocuflox
Ofloxacin · Ophthalmic · Quinolone Antimicrobial
Last checked: Nov 20, 2026Latest source record: Nov 16, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Jul 30, 1993
Approved uses
2
Original approval plus efficacy supplements
Registered trials
404
122 Phase 3, 26 recruiting
FAERS reports
7,237
5,537 serious, 615 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 13, 2024.
INDICATIONS AND USAGE OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 22, 1996 Supplement 3 · Efficacy
- Jul 30, 1993 Original approval · Type 3 - New Dosage Form Pediatric Medical ReviewPediatric Medical ReviewPediatric Written Request
1 products under this application
- OCUFLOX · OFLOXACIN 0.3% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Ofloxacin" as an intervention, any sponsor and status, largest first.
- Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract SurgeryPivotal-lookingCompleted
City St George's, University of LondonAcademic, hospital or other
NCT00136344 · 35,000 participants · Start Sep 2003
Drug: Cefuroxime; Levofloxacin · For: Endophthalmitis
Sites: Salzburg, Austria; Antwerp, Belgium; Ghent, Belgium · 24 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Community-based Helicobacter Pylori EradicationStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT00155389 · 5,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2015
Drug: Helicobacter pylori eradication · For: Helicobacter Pylori Infection
Sites: Taipei, Taiwan · 2 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- Shortened Regimens for Drug-susceptible Pulmonary TuberculosisPivotal-lookingStatus unknown
Beijing Chest HospitalAcademic, hospital or other
NCT02901288 · 3,900 participants (planned) · Start Aug 2016 · Primary completion Dec 2018
Drug: Isoniazid; Rifampicin and 3 more · For: Tuberculosis, Pulmonary
Sites: Hefei, China; Beijing, China; Chongqing, China · 35 sites in all
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TBPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06568484 · 2,530 participants (planned) · Start May 8, 2026 · Primary completion Jul 2027
Drug: Bedaquiline; Levofloxacin · For: Tuberculosis, Latent
Sites: Ulaanbaatar, Mongolia; Lima, Peru; Mbeya, Tanzania · 8 sites in all
- A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without LevofloxacinPivotal-lookingRecruiting
Tuberculosis Research Centre, IndiaGovernment (non-federal)
NCT07947056 · 2,500 participants (planned) · Start Jun 6, 2026 · Primary completion Dec 2028
Drug: Standard 6-month treatment regimen; High dose Rifampicin (25mg/Kg) and 2 more · For: Tuberculosis, Pulmonary, Drug Sensitive
Sites: Guntur, India; Guwahati, India; Rajkot, India · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye pain366
- drug ineffective349
- off label use318
- headache291
- pain274
- fatigue272
- arthralgia260
- nausea257
- diarrhoea252
- acute kidney injury248
- anxiety215
- pyrexia213
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 131 |
| 2005 | 103 |
| 2006 | 98 |
| 2007 | 96 |
| 2008 | 111 |
| 2009 | 141 |
| 2010 | 93 |
| 2011 | 203 |
| 2012 | 242 |
| 2013 | 151 |
| 2014 | 154 |
| 2015 | 218 |
| 2016 | 289 |
| 2017 | 375 |
| 2018 | 531 |
| 2019 | 594 |
| 2020 | 546 |
| 2021 | 582 |
| 2022 | 617 |
| 2023 | 640 |
| 2024 | 508 |
| 2025 | 499 |
| 2026 | 314 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ocuflox (Ofloxacin)
2024 spending
$7K
Beneficiaries
62
73 claims
Per beneficiary
$108
$15.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,885 |
| 2021 | $7,765 |
| 2022 | $9,166 |
| 2023 | $5,664 |
| 2024 | $6,679 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Doxycycline for Mild-to-Moderate Community-Acquired Pneumonia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Choi SH, Cesar A, Snow TAC, et al. · Clin Infect Dis 2023 · Meta-Analysis, Systematic Review
- Topical antibiotics for treating bacterial keratitis: a network meta-analysis.
Song A, Yang Y, Henein C, et al. · Cochrane Database Syst Rev 2025 · Network Meta-Analysis, Systematic Review
- Fluoroquinolones for treating tuberculosis.
Ziganshina LE, Squire SB · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Fluoroquinolones for treating tuberculosis.
Ziganshina LE, Vizel AA, Squire SB · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Antibiotics for treating human brucellosis.
Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Lafaurie M, Chevret S, Fontaine JP, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.